NEW YORK, April 23, 2024 /PRNewswire/ — The global radiopharmaceuticals market size is estimated to grow by USD 4612.62 mn from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of almost 10.22% during the forecast period. The prevalence of neurological disorders knows no boundaries, transcending age, gender, race, and geography. Their omnipresence underscores the urgent need for effective interventions to mitigate their impact. With an ever-increasing number of individuals worldwide grappling with these conditions, the societal burden looms large, demanding innovative approaches to address them.
Technavio has announced its latest market research report titled Global Radiopharmaceuticals Market 2023-2027
For more insights on the forecast market size and historic data (2017 – 2021) – Buy Report
Transforming Diagnostics and Treatment:
Enter radiopharmaceuticals, a cornerstone in the arsenal against neurological disorders. These specialized pharmaceuticals play a pivotal role in both diagnosis and treatment, offering precise insights into neurological conditions while facilitating targeted therapeutic interventions. Their efficacy in navigating the complexities of neurological disorders marks them as indispensable assets in the healthcare landscape.
Driving Forces Behind Market Growth:
As the incidence of neurological disorders continues to escalate, so does the demand for radiopharmaceuticals. This symbiotic relationship between neurological disorders and the radiopharmaceutical market underscores a pivotal driver of growth. With neurological disorders exerting an ever-expanding influence on global health, the corresponding surge in demand for radiopharmaceuticals becomes inevitable.
For inputs on more Market Drivers, trends, & Challenges- Request a sample report!
Research Analysis
The Radiopharmaceuticals Market encompasses the production and distribution of nuclear medicines, primarily used in the diagnosis and therapeutics of chronic diseases. Personalized therapy is a significant trend in this market, with the use of technetium-99m and gallium-68, among other radioisotopes, playing a crucial role. Chronic illnesses such as cancer, particularly in the geriatric population, are major indications for the use of radiopharmaceuticals. Companies like Jubilant Radiopharma, IBA Worldwide, and Medical Solutions are key players in this market. Medical imaging centers and hospitals are the primary end-users, contributing significantly to healthcare expenditure. Drug development techniques and alternative treatments are also driving the growth of the radiopharmaceuticals market in the diagnostic and therapeutic sectors.
Market Research Overview
The Radiopharmaceuticals Market is a significant sector in the healthcare industry, characterized by the production and distribution of diagnostic and therapeutic agents using radioisotopes. These substances, such as Technetium-99m and Gallium-68, are essential for various medical imaging techniques and cancer treatments. The market is driven by the increasing demand for early and accurate disease diagnosis and the growing prevalence of chronic diseases. The use of advanced technologies, such as PET and SPECT imaging, and the development of new radiopharmaceuticals are key trends in this market. The market is also influenced by regulatory frameworks and reimbursement policies. The market is projected to grow at a steady pace in the coming years, with North America and Europe being major contributors. The market is competitive, with key players including Cardionovum AG, GE Healthcare, and Lantheus Medical Imaging.
For inputs on more Market Drivers, trends, & Challenges- Request a sample report!
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio